XOMA has built a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research. XOMA focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. XOMA's lead product candidate, gevokizumab (IL-1 beta modulating antibody), is in a global Phase 3 program in non-infectious uveitis with its partner SERVIER and multiple proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major effect on the treatment of diabetes.
In 2010, XOMA partnered with Servier, France's leading independent pharmaceutical company, for the development of XOMA’s lead product gevokizumab (IL-1 beta modulating antibody). This collaboration brings together Servier's resources and expertise in pharmaceutical product development and commercialization with XOMA's expertise in biologics clinical development and manufacturing capabilities.
Today, XOMA’s principal activities are centered on the advancement of gevokizumab and the advancement of its preclinical pipeline.
XOMA's antibody technology platforms include an unmatched collection of antibody phage display libraries and proprietary Human Engineering™, Bacterial Cell Expression (BCE), affinity maturation and manufacturing technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. Overall, 60 pharmaceutical and biotechnology companies have signed BCE licenses, and several licensed product candidates are currently in clinical development. XOMA is entitled to development-related milestones and royalties on antibodies covered under these licenses.
Mar 11, 2014 at 1:00 PM PT
26th Annual ROTH Conference
Mar 4, 2014 at 3:00 PM PT
Gevokizumab POC Program Update and Fourth Quarter / Full Year 2013 Financial Results Conference Call